The effects of repaglinide treatment on FPG ( p < 0.01 ) , FINS ( p < 0.05 ) and HOMA-IR ( p < 0.001 ) were reduced in patients with T2DM carrying the NOS1AP rs12742393 risk C allele compared with the AA genotype carriers .